SETD2 and breast carcinoma: In addition, SETD2 mutation is associated with the development and progression of several cancers, such as clear cell renal cell carcinoma, breast carcinoma and colorectal cancer, and is involved in chemotherapy resistance in leukemia patients 7,10-12.